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Multiple Sclerosis (MS) is the most common neurological disease worldwide. The article 
presents the symptoms, the etiology and the diagnosis of MS. It also refers to the 
neuropsychological data and cognitive disorders in Multiple Sclerosis, to the  MS 
treatment and to the developments in MS research. 
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Multiple Sclerosis (MS) is the most 
common neurological disease 
worldwide. It has infected 2.5 million 
people until today. Evidence suggests 
that this condition is more common in 
cold climates: the more far away a 
country from Ecuador, the greater the 
incidence of the disease. Disease’s 
symptoms were first recognized in 1868 
by the French neurologist Charcot 
(Noseworthy et al, 2000). 
 
Definition and Description 
MS is a chronic disease of the central 
nervous system, which consists of the 
brain and the spinal cord. The first 
symptom usually occurs around the age 
of 20 and up to 50, more rarely before 12 
or after 50. It affects women more than 
men in a ratio of about 2: 1 and more 
often the white race (Wehman-Tubbs et 
al , 2005). 
This disease behaves like an autoimmune 
disease. That is, the body does not 
recognize some tissues for its own and 
attacks them causing damage.  
Specifically in MS, for reasons that 
medicine can not fully explain, the 
immune system fights the myelin shell as 
"foreign" and destroys it as if it were a 
pathogenic invader, such as a bacterium 
or a virus. Part of the myelin of the 
nerves is infected and irritated. When the 
inflammation subsides, it is likely to 
leave no scar. But if it continues, then 
myelin is destroyed at that point, leaving 
a scar called plaque or sclerosis. This 
process is called demyelination. 
Thus, the symptoms are caused by the 
demyelination and the upcoming 
destruction of the nerve shafts in the 
central nervous system. It has not yet 
been proven whether this false immune 
response is a primary or secondary factor 
in the disease. Because the scars appear 
in different parts of the brain and / or the 
spinal cord, this is why the disease is 
called multiple sclerosis (Dutta & Trapp, 
2007). 
We know that the immune system is 
based on white blood cells, of which 
there are many different types. Those 
primarily associated with multiple 
sclerosis are macrophages and T-cells or 
T-cells that attack myelin. 
Demyelination can affect both the motor 
and the sensory nerves of the central 
nervous system and can thus affect 
movement, touch or other sensations 
(Whitwell et al, 2007). 
 
Symptoms 
Symptoms in MS vary greatly depending 
on which nerves are affected. Some are 
obvious, but others such as fatigue, mood 
swings, recent memory loss, and 
difficulty in concentrating are usually 
unclear or "hidden" symptoms that are 
difficult to describe in others (Wehman-
Tubbs et al, 2005). 
However, there are some symptoms 
common to many sufferers, such as 
(Wehman-Tubbs et al, 2005): 
• Double vision or blurred eyes 
• Weakness or disability of one or both 
ends 
• Changing the sensation of the hands or 
feet, such as numbness - often described 
as "walking on cotton" 
• Dizziness or instability 
• Fatigue disproportionate to our 
activities or unexpected tiredness 
• Need for frequent or urgent urination or 
difficulty in passing urine 
As can be seen from the above, there is 
no single type of multiple sclerosis. 
Every person has symptoms that the 
other may not have. But also the 
symptoms of the individual can vary 
from time to time. There is no "standard" 
MS. It is a "personal" condition and so a 
general description of the disease or a 
certain prognosis is not possible. About 
85% of the people with the disease will 
have their recurrent form, that is, with 
outbursts and recessions. During the 
excitement or throbbing, new symptoms 
appear or reappear earlier that they have 
subsided. 
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When the symptoms of thrust subsided 
altogether or partially, then we say that 
we are experiencing a recession that can 
last for weeks, even months and even 
years. Another form of MS is the 
primary progressive form of the disease. 
According to this form, the sufferers will 
have a slow progression of some 
symptoms that will not go away over 
time. Changes can begin gently and 
gradually and evolve to create a steady 
decrease in physical or mental abilities. 
Perhaps then it will be harder to 
understand the "best" of the "worst" 
periods. 
In addition, we have the secondary 
progressive form, where an initial period 
of exacerbations and relapses is followed 
by a steady worsening of the symptoms. 
50% of people with relapsing form of 
MS develop this form of disease 10 years 
after the initial diagnosis. Finally, in the 
progressive - recurrent form, there is a 
steady deterioration of the disease from 
the beginning with acute relapses, but 
this is also the most rare form of MS. 
It is worth noting that most people with 
MS have some mild form of the disease 
and never get severe disabilities. Some, 
however, need to face some degree of 
disability from time to time. Others may 
present that form of disease that evolves 
rapidly and progressively and results in a 
great deal of disability (Noseworthy et 
al, 2000). 
It is important to mention here the brain 
atrophy, which begins in the early stages 
of the disease and is a determining factor 
in its course. The atrophy presented is 
based on degenerative processes and 
forms the basis for innovative 




MS is not solely due to a specific cause. 
There seem to be many factors that play 
a role in its development. The most 
prevalent versions report the viral 
infections and autoimmune mechanisms 
that we explained above. Recent research 
suggests the role of Epstein-Barr virus 
(EBV) in the onset of this disease. This 
particular virus, when infecting the 
human organism, in most cases causes 
infectious mononucleosis. In some cases, 
however, it appears to contribute to the 
development of MS. Scientists argue 
that people who develop the condition 
may have a genetic predisposition. In 
fact, the latest investigations link mainly 
chromosome 6 to this subject, but also 
some other chromosomes such as 6, 2, 3, 
7, 11, 17, 19 and X. Thus an upcoming 
environmental viral antigen (such as an 
infection) in persons with inherited 
predisposition, can bring the 
manifestation of the disease. This is 
usually done early in a person's life, 
especially during puberty (Kurtzke, 
1993; Søresen & Ransohoff, 1998). 
Recent studies have linked the 
deterioration of MS symptoms with G-
CSF, a granulocyte stimulating factor, 
which appears to increase the adhesion 
of T-lymphocytes to the ECM. In 
addition, recent tissue analyzes of MS 
patients indicate molecular targets 
associated with mitochondrial function 
and specific isoforms of ion channels as 
contributors to demyelination (Kurtzke, 
1993). 
Regarding relapses, some scientists 
consider them to be responsible for the 
concentration of disability, and generally 
the clinical course of the disease, while 
other researchers claim that relapses do 
not appreciably affect irreparable 
disability in the long-term course of MS 
(Foong et al, 1998). 
 
Diagnosis 
It is difficult to diagnose multiple 
sclerosis because there is no examination 
that can be 100% sure. It may take a long 
time to suspect that the symptoms 
presented by a person are due to the 
particular condition. Examinations are 
done to rule out the possibility of other 
illnesses and lead to the possible 
diagnosis of MS in "abduction in 
absentia". There are various methods for  
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this purpose (Noseworthy et al, 2000): 
1. Medical history 
2. Neurological examination: A 
systemic examination of the nervous 
system can be performed with a series of 
reflex tests (knocking with the knee 
hammer) or measuring the reactions to 
external irritations (needle sticking). 
Thus, the physician is able to observe 
any malfunctions occurring in the 
nervous system. 
3. Exams for Dynamic Vision and 
Hearing: Demyelination may cause a 
delay in the transmission of nerve 
messages. These tests measure the time 
the brain needs to accept and then 
convert a stimulus. For this purpose, 
small electrodes are placed on the head 
of the subject and control the electrical 
waves of the brain after an optical or 
acoustic stimulus. When there are 
demyelinating plaques in the central 
nervous system, it may be delayed. 
4. Lumbar puncture: This test shows 
whether there are antibody to the 
cerebrospinal fluid that can be created by 
MS. During the examination, a small 
amount of fluid is taken from the spine at 
the lumbar spine with a needle. The 
results of this test may be evidence of 
multiple sclerosis but are not conclusive. 
This method also blocks other central 
nervous system diseases with similar 
symptoms to MS. 
5. Magnetic resonance imaging: These 
are radiographs of the brain and spinal 
cord, showing the areas affected by MS. 
But it is a strong indication, along with 
other symptoms of patient history and 
doctor's examination, and in 95% of MS 
cases this is positive. 
Neuropsychological Data and 
Cognitive Disorders in Multiple 
Sclerosis 
Neuropsychology plays an important role 
in the research and the best possible 
treatment of MS. The neuropsychologist, 
in cases of MS patients, is required to 
assess the patient's cognitive abilities and 
to judge whether they are affected by the 
condition and how. In addition, he must 
use his or her knowledge to make the 
person's quality of life as good as 
possible, helping to partially repair the 
upcoming damages and their 
consequences. 
The assessment of the nature and extent 
of cognitive changes in MS has only 
begun in recent decades. In the 1970s, 
there was the view that this disease only 
resulted in kinetic dysfunctions. In 1977, 
it was estimated that only 5% of MS 
patients had cognitive changes or 
linguistic dysfunctions (Joy & Johnston, 
2001). New neuropsychological studies 
have shown that half of the MS 
population may experience cognitive 
dysfunctions (Rao, 1995). 
Cognitive dysfunctions in a disease vary 
from person to person and are mainly 
dependent on the location of brain 
damage, extent of lesions and incidence 
of episodes. Cognitive dysfunctions are 
not generalized but rather localized in 
specific cognitive processes. These 
dysfunctions were named by Rao (1986) 
"subcortical dementia". Many people 
may even experience personality 
disorders, apathy, depression or 
euphoria. They are still experiencing 
reduced judgment, difficulty in 
organizing and performing tasks. 
Fischer and his colleagues (1994) also 
report a particular difficulty with the 
long-term and short-term memory of 20-
40% of people with cognitive 
difficulties. 
More specifically, the proportion of 
people experiencing cognitive 
dysfunction as a result of MS has 
problems with perception, memory, 
attention, orientation, judgment and 
thought. More analytically, the functions 
of thought slow down, resulting in 
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incoherent and incomprehensible reason 
(DeSousa, 2002). 
From the early stages of the illness, the 
speed of information processing is 
already beginning to decrease in people 
with MS. As the disease progresses and 
develops, working memory is also 
affected, thus undermining new learning. 
It is remarkable that patients with MS 
have difficulty remembering to do 
something at a given time (delayed 
intention task). This seems to be due to 
their failure to remember the content of 
their intention (retrospective memory), 
and not to failure to remember that they 
intend to do something or when it should 
be (prospective memory). In addition, 
related research also affects the 
conceptual reasoning. Research shows 
that people with this disease have 
difficulties in learning verbal and visual-
spatial works. Regarding this issue, some 
scientists report that these difficulties are 
causing some of the memory problems, 
since they prevent the person from 
restraining what they need to hold back. 
Thus, some strategies for better long-
term memory in MS are the time-
consuming and many-time learning tests 
that allow patients to retain more data 
and make better coding. Additionally, 
minimizing distractions during and after 
learning can help to improve learning 
efficiency and better recall of what has 
been learned. (DeSousa et al, 2002; 
Franklin et al., 1989; Lensch et al., 
1996). 
 As far as language functions are 
concerned, both patients with the 
recurrent form, but especially those with 
the primary progressive form of the 
disease, seem to lack language skills 
such as the naming of objects - due to 
lack of access to semantic memory - 
understanding and verbal competency. 
In general, surveys that have been done 
to MS patients indicate problems of 
understanding ambiguous proposals and 
transpositions, drawing conclusions and 
recreating suggestions, as well as 
problems in vocabulary and semantic 
understanding. It is understandable that 
linguistic difficulties also exacerbate the 
difficulties encountered in memory 
functions in patients with this condition 
(Fischer et al, 1994). 
As the researchers say, the above 
neuropsychological problems are due in 
part to the demyelination of neural 
networks that start from the prefrontal 
cortex and end up in the white matter of 
the brain. As far as language problems 
are concerned, they are associated with 
areas of the cerebral cortex as well as 
with subcortical areas such as the 
chamber and basal ganglia (Rao, 1986). 
It is clear that all of the above cognitive 
problems that afflict patients with MS 
have obvious implications for their daily 
lives. They can affect many areas, from 
simple consultation with people around 
them, to obstruction of their work, and 
can not lead to psychopathology. From 
socio-epidemiological investigations that 
have been made, it is known that MS 
causes 50-80% of patients to lose their 
job within 10 years of the onset of the 
disease (Calabrese, 2006). 
That is why it is important to continue 
research on these topics and to develop 
new, more sensitive neuropsychological 
tools for their detection, in addition to 
those already in use, such as aphids 
diagnosis tests and various memory tests. 
Through ongoing research, more and 
more strategies are being developed to 
improve the cognitive function of people 
with MS, such as those mentioned above 
for memory, giving more and more hope 
to millions of people for a better quality 
of life (Joy & Johnston, 2001). 
However, because not all people have 
cognitive impairment, it is important to 
understand the factors that may or may 
not contribute to cognitive dysfunction. 
The degree of cognitive dysfunction does 
not correlate strongly with the degree of 
neurological disability (Amato et al, 
1995). DeSousa et al. (2002) note that 
cognitive dysfunction can develop at any 
time during the progression of the 
disease, in the presence or absence of 
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neurological disability. Other factors 
that positively correlate with the 
presence of cognitive dysfunctions are 
the percentage of the brain that shows 
the lesions of demyelinating foci in the 
brain as they are distinguished by 
magnetic resonance imaging (Rovaris & 
Filippi, 2000). Franklin et al. (1989) 
argue that severe loss of cognitive 
functions is likely in people with MS that 
have the following characteristics: 
chronic, progressive illness, depression 
or bipolar disorder, cognitive difficulties 
at work or at home, specifically in 
activities which require attention, 
memory or complex problem-solving 
skills, and finally when the clinical 
picture of the disease (demyelinating foci 
in the brain) is distinguished in the 
magnetic resonance imaging of the brain. 
Treatment 
Modern MS therapies are more effective 
in the inflammatory phase of the disease 
because they can intervene at various 
stages of the autoimmune course. In 
particular, acute exacerbations can be 
treated with corticoids, pills, injections 
or intravenously, since corticoids have 
anti-inflammatory and 
immunosuppressive action. Other 
medications aim to modify the course of 
the condition by suppressing the immune 
system. This is achieved with drugs 
based on azathioprine or 
cyclophosphamide and is indicated for 
the most severe forms of the disease. 
One of the most promising and 
impressive discoveries of recent years is 
interferon B and glatiramer acetate. 
These drugs seem to reduce the 
incidence of recurrences in the recurrent 
form of MS, as well as to reduce the 
number and size of new plaques seen in 
MRI. Unfortunately, they have high 
costs and some side effects (Calabresi, 
2002; Filippini et al, 2003). 
However, with regard to interferons in 
particular, research shows that they play 
a crucial role in the regulation of 
endogenous and adaptable immune 
system responses and reduce pro-
inflammatory responses such as 
autoimmune response to MS (Filippini et 
al., 2003). 
New hopes are given by statin therapies 
(eg, Sivasatin), which cause a large 
reduction in the number and magnitude 
of brain damage. In particular, they 
reduce the proliferation of T-type cells, 
thus, by extension, alter to the best 
pathological inflammatory responses 
caused by T-lymphocyte disorders, and 
their side effects are rare (Wehman-
Tubbs, 2005). 
Particularly effective are 
immunomodulatory therapies that 
modulate the function of antibodies as 
well as functions that suppress the 
function of antibodies that function 
against the inflammatory course of the 
disease. 
In addition to the above, there are drugs 
for the individual symptoms of multiple 
sclerosis, e.g. for pain, spasticity, tremor, 
urinary tract disorder, sexual dysfunction 
and depression to promote quality of life 
and patient self-care (Lensch et al, 2006). 
In addition, when the patient experiences 
a cognitive impairment, there are 
opportunities for intervention so that 
both he and his family live as normal a 
life as possible. More specifically, there 
are psycho-educational programs, which 
have a role of both counseling and 
neuropsychological rehabilitation, to 
give patients the skills to cope with the 
psychosocial, emotional and cognitive 
problems that arise. They inform the 
patient of their symptoms and their 
causes, and try to reduce the stress that 
occurs with various behavioral strategies 
that increase the person's ability to self-
handle (Lensch et al, 2006). 
Developments in MS research 
Gene expression studies using peripheral 
blood mononuclear cells help to 
understand relevant disease expressions, 
regulate therapeutic responses to various 
drugs to predict the outcome and, in the 
longer term, to determine the key 
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molecules that contribute to the 
pathogenesis of Dutta & Trapp , 2007). 
One of the latest advances in MS is 
neuroprotection. It focuses on strategies 
to prevent irreparable damage to various 
neuronal and glial cells and to promote 
myelin regeneration. One strategy is the 
use of embryonic stem cells derived from 
the bone nucleus. Hematopoietic and 
non-hematopoietic cells can differentiate 
into glial and neuronal cells. They can 
therefore have a therapeutic effect on MS 
(Joy & Johnston, 2001). 
In conclusion, it seems that MS is an 
issue that still raises the interest of 
researchers. Research continues at a 
rapid pace, interpretations and therapies 
are evolving, giving new hope to 
thousands across the globe. 
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